http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108969479-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 2018-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108969479-B |
| titleOfInvention | Method for constructing reduction response type anticancer nano-drug by polypeptide-drug co-assembly |
| abstract | The invention discloses a method for constructing a reduction response type anticancer nano-drug by polypeptide-drug co-assembly, which designs a pure polypeptide containing disulfide bonds, and realizes the co-assembly of the polypeptide and the drug by utilizing the interaction between the pure polypeptide and the anticancer drug to obtain the anticancer nano-drug. The polypeptide used in the invention only consists of amino acid, does not need to modify other non-peptide groups, and is simple to synthesize. The used polypeptide has good biocompatibility, low biotoxicity and easy degradation in vivo. The used polypeptide has sensitive response to GSH, can realize the rapid release of the drug at the tumor part, and improves the utilization efficiency of the drug. The nanometer medicine can stably play an anticancer role in a living body, and does not generate obvious toxic or side effect on healthy tissues. |
| priorityDate | 2018-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.